Mesothelioma
Studies & trials
-
ASSESS-Meso*
A multi-centre, prospective, longitudinal study aiming to improve knowledge about several aspects of mesothelioma. This study is not yet published."
-
DIAPHRAGM
A national, prospective, observational study investigating the role of biomarkers in the diagnosis of mesothelioma. This study is not yet published.
-
MARS2
A national randomised controlled trial comparing the outcomes of surgery for mesothelioma with non-surgical standard care. This study is not yet published.
-
MesobanK
A national biobank of mesothelioma tissue samples which aims to improve resources for future mesothelioma research. This study is not yet published.
-
MESO-Trap
A national randomised controlled trial comparing surgical decortication with indwelling pleural catheter for patients with mesothelioma and trapped lung. This study is not yet published.
-
RESPECT-Meso
A national randomised controlled trial comparing standard care with early specialist palliative care for patients with mesothelioma.
-
SMART*
A national randomised controlled trial comparing early radiotherapy to symptom-led radiotherapy following pleural intervention in mesothelioma.
-
SWAMP*
A longitudinal study examining the role of PET-CT and various biomarkers in the diagnosis and monitoring of mesothelioma.
-
TILT*
A feasibility randomised controlled trial of intrapleural immunotherapy for mesothelioma. This study is not yet published.
-
Zol-A*
A feasibility randomised controlled trial exploring the effect of zoledronic acid in patients with mesothelioma. This study is not yet published.
Mesothelioma
is a type of cancer which most commonly originates in the pleural membranes. It is strongly linked to past exposure to asbestos. It remains incurable and carries a poor prognosis for many patients. Incidence in the UK is rising and is expected to do so for at least the next decade.
For more information on our current and past mesothelioma study involvement, follow the links to left (* indicates Bristol led)
